This study conducted a model-based cost-effectiveness analysis comparing GAE performed by IRs and ICs for the treatment of symptomatic knee osteoarthritis.
This study conducted a model-based cost-effectiveness analysis comparing GAE performed by IRs and ICs for the treatment of symptomatic knee osteoarthritis.
The MOTIV BTK trial met both its primary safety and efficacy endpoints, demonstrating that the MOTIV scaffold provides a statistically significant improvement in clinical outcomes compared to the current standard of care, balloon angioplasty.
The MOTIV BTK trial met both its primary safety and efficacy endpoints, demonstrating that the MOTIV scaffold provides a statistically significant improvement in clinical outcomes compared to the current standard of care, balloon angioplasty.
Initial data from the Esprit™ BTK Post-Approval Study (PAS) presented at the Charing Cross Symposium in London, UK, revealed promising 30-day results that...
Initial data from the Esprit™ BTK Post-Approval Study (PAS) presented at the Charing Cross Symposium in London, UK, revealed promising 30-day results that...
LOS ALTOS, Calif. — Efemoral Medical announced that at the Charing Cross Symposium in London, UK, EFEMORAL I Principal Investigator Prof. Andrew Holden of Auckland, NZ, presented the long-term results of the first 40 patients...
LOS ALTOS, Calif. — Efemoral Medical announced that at the Charing Cross Symposium in London, UK, EFEMORAL I Principal Investigator Prof. Andrew Holden of Auckland, NZ, presented the long-term results of the first 40 patients...
Post-approval study’s primary cohort shows 70.2% target lesion primary patency consistent with pivotal randomized controlled trial results in a challenging population1
Medtronic, a global leader in healthcare technology, today announced...
Post-approval study’s primary cohort shows 70.2% target lesion primary patency consistent with pivotal randomized controlled trial results in a challenging population1
Medtronic, a global leader in healthcare technology, today announced...
August 5-8 event at new location in Boston highlights DVA, drug-eluting tech, eight first-to-podium research presentations, and featuring a cadaver lab.
August 5-8 event at new location in Boston highlights DVA, drug-eluting tech, eight first-to-podium research presentations, and featuring a cadaver lab.
DEEPER REVEAL is a prospective, non-randomized, multicenter study evaluating use of the Spur Peripheral Retrievable Stent System following predilatation in patients with chronic limb-threatening ischemia (CLTI) and below-the-knee (BTK)...
DEEPER REVEAL is a prospective, non-randomized, multicenter study evaluating use of the Spur Peripheral Retrievable Stent System following predilatation in patients with chronic limb-threatening ischemia (CLTI) and below-the-knee (BTK)...
A prospective pilot study evaluated the impact of a novel combination of pulsed electric field ablation and stereotactic body radiation therapy on health-related quality of life and pulmonary function in patients with oligometastatic or...
A prospective pilot study evaluated the impact of a novel combination of pulsed electric field ablation and stereotactic body radiation therapy on health-related quality of life and pulmonary function in patients with oligometastatic or...
“Together with the initial STORM PE results, which demonstrated faster reperfusion and improved right ventricular recovery, this 90-day data highlights significant patient centered benefits of CAVT in intermediate high risk PE,” said Robert...
“Together with the initial STORM PE results, which demonstrated faster reperfusion and improved right ventricular recovery, this 90-day data highlights significant patient centered benefits of CAVT in intermediate high risk PE,” said Robert...
iMRI enables a minimally invasive interventional practice ideal for precise soft tissue imaging, tumor targeting, biopsy and future ablation therapies, representing the future of radiation-free, image-guided care.
iMRI enables a minimally invasive interventional practice ideal for precise soft tissue imaging, tumor targeting, biopsy and future ablation therapies, representing the future of radiation-free, image-guided care.
